c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
about
Multifunctional Abl kinases in health and diseaseNeuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathwaysDisease-modifying therapeutic directions for Lewy-Body dementiasc-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's DiseaseDefying c-Abl signaling circuits through small allosteric compounds.Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approachAlpha-synuclein function and dysfunction on cellular membranes.Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-SynucleinopathyRecent advances in applying mass spectrometry and systems biology to determine brain dynamics.A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegenerationNilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death.Protein phosphorylation in neurodegeneration: friend or foe?Basic science breaks through: New therapeutic advances in Parkinson's disease.Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?Nilotinib - Differentiating the Hope from the Hype.Molecular changes in the postmortem parkinsonian brain.The c-Abl inhibitor in Parkinson disease.The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.TDP-43 in the spectrum of MND-FTLD pathologies.Phosphorylation Interferes with Maturation of Amyloid-β Fibrillar Structure in the N Terminus.Phosphorylation modifies the molecular stability of β-amyloid deposits.Semisynthetic and in Vitro Phosphorylation of Alpha-Synuclein at Y39 Promotes Functional Partly Helical Membrane-Bound States Resembling Those Induced by PD Mutations.An enhanced recombinant amino-terminal acetylation system and novel in vivo high-throughput screen for molecules affecting α-synuclein oligomerisation.Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease.c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.c-Abl-mediated Drp1 phosphorylation promotes oxidative stress-induced mitochondrial fragmentation and neuronal cell death.Biological and Clinical Implications of Comorbidities in Parkinson's Disease.The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis.Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.Ganglioside Metabolism and Parkinson's Disease.Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System.Yeast reveals similar molecular mechanisms underlying alpha- and beta-synuclein toxicity.Structure and dynamics of the extended-helix state of alpha-synuclein: Intrinsic lability of the linker region.Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease.The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
P2860
Q26771277-639E99A9-5FC4-4104-9310-D64D0A329809Q26779424-889F15A7-5065-4F1C-9665-B1EA4EBF0495Q26782907-9DEA28B3-D6CA-4FB4-AEB2-ED5599530BDBQ28070292-4CDFFF83-C5D8-4C8F-8DAE-ADAD0E30794DQ30009269-2748579B-CB93-4550-A060-32EBEA800483Q33364337-D94D66E7-EC8A-4054-93AB-7C91A94F074EQ34774324-4E0B92A9-C38F-4C4F-878A-EFB84135503AQ35019131-7C3EB828-70C6-497B-B070-5070684A4F90Q36379339-0DF79300-4052-4D32-997C-47117A4307D5Q37004163-9E1E1B19-C68E-41F7-BD95-C2BF22D6B371Q37137895-F8D171AD-31EA-4D25-AA71-414708CAE977Q37225128-5AD0A477-72BC-4329-9EA4-4A570D7CE30EQ37354028-2007124F-EDD4-4575-8CFB-53F4A12E013CQ38214594-F1657587-5CFC-461D-BED9-3985CB81442EQ38547662-D5D3A0B5-E188-488F-9D79-E5DC895CED6AQ38652662-FC128A40-4291-494E-8664-055B64596BC0Q38765856-06B5D2F1-FD4B-4C4D-80CF-1BEA73C729E5Q38785080-37D72E2F-1086-4759-89A6-E51DEA82A270Q38840128-FFAFAB0D-90E1-44BC-B72C-549D7D977BD6Q38887346-62035F76-1041-42FC-A60C-FD7CC4DB50EEQ39081447-0DEFB2B8-26E2-4D4D-B253-67F8DE7DE9A1Q39136811-251F3312-9F27-42ED-A8B1-160BD9599E6AQ39421928-5F1ED787-ADCA-40E6-80CA-8D24E12520AAQ39716461-051B287F-16CD-428F-888B-84D97D160963Q40249589-E264498D-61E7-48EE-89F2-C281CFB50440Q41728474-BABEDBFE-2E18-4B8A-B214-F5E2FDB2AB00Q42291075-5FEF70F4-109B-4C17-9C70-6223CD3AACF2Q42653035-CCBBC4F0-66A5-4E88-8E0D-0055C28B7993Q47124745-2D3044FA-5E78-4ADC-B8E9-22C9F8E4F407Q47133507-FACB5576-455F-4D57-B4D4-C250FB0E4179Q47137783-5C77A2B3-9D64-4E88-9156-F0B102499C65Q47714809-FE31D4CB-06A9-480B-81F0-D061D1209015Q48829255-58A67A0A-91C7-45C5-BD18-3EDE9B0D9A2EQ49829715-535FC18A-B522-4B62-80C5-DA23ABF94606Q50648904-A68D5FF9-AEFF-4C21-ABA8-FD9710BC7913Q52146660-BC718ACA-0E97-4B5E-A25E-D661990C6DA7Q52319335-65C38F2B-0381-4800-92C7-AF920755F59BQ52714245-B9309B04-2BC1-4E16-897D-838A42D0FD5FQ55401120-45C5ECB1-C4EA-4F05-98A6-EA37DE3247EB
P2860
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@ast
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@en
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@en-gb
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@nl
type
label
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@ast
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@en
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@en-gb
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@nl
prefLabel
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@ast
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@en
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@en-gb
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
c-Abl phosphorylates α-synucle ...... genesis of Parkinson's disease
@en
P2093
Abid Oueslati
Alejandro Bisquertt
Allan J Lamontanara
Amanda Gysbers
Anne-Laure Mahul-Mellier
David Eliezer
Igor Dikiy
P2860
P304
P3181
P356
10.1093/HMG/DDT674
P407
P577
2014-06-01T00:00:00Z